Secondary carnitine deficiency can be caused by increased losses, pharmacological therapy, a number of inherited metabolic disorders [38], poor diet or malabsorption of carnitine, from increased renal tubular loss of free carnitine (Fanconi syndrome), haemodialysis, peritoneal dialysis, or the increased excretion of acylcarnitines[39] with certain drugs
DHAR catalyses the reduction of DHA to AsA using glutathione (GSH) as a hydrogen donor before the spontaneous hydrolysis of DHA to irreversibly form 2,3-diketogulonic acid
Patient-driven diabetes care of the future in the technology era
It is about restoring capacity, rebuilding strength, improving mechanics, and safely returning to activity
This study develops a compound, JMF4073, inhibiting thymidylate (TMP) and cytidylate (CMP) kinases, aiming for a new therapy against TKI-resistant CML